HOW ORGANIZATIONAL STRUCTURE AIDS BUSINESS PERFORMANCE.

This paper examined how organizational structure aids business performance. Existing studies have shown that it is nearly impossible for an organization to exist without a defined organizational structure. Studies also revealed that the main purpose of organizational structure is the division of work among members of the organization, and the co-ordination of their activities so they are directed towards the goals and objectives of the organization. The sources of data used for this research are from secondary sources. The secondary sources are from journals and conference articles, the internet, newspapers, magazines and textbooks. This research found that organizational structure has a significant impact on the performance of business organizations. Hence, the researchers recommend that business organizations should endeavor to develop a properly defined structure for the organization so as to achieve set objectives

BUSINESS STRATEGY AS A CONTRIBUTOR TO ORGANIZATIONAL PERFORMANCE

Strategies to enhance performance in business organizations are of great importance to organization leaders in today‟s business environment. Research relating to both large, medium, small and micro sized firms constantly emphasized a positive relationship between business strategies, management activities and organisational performance. This is because it is often detailed that best business strategies produce outstanding organisational performance. This study reviewed diverse empirical literature on business strategies and their effects on organisational performance. The authors were able to ascertain from various literature reviewed that business strategies have a major role to play in enhancing organisational performance. This study finds that recognizing the causes of organizational performance is important especially in the perspective of the current global competitive and turbulent business environment. In addition, it helps an organisation to identify those factors that should be emphasized to improve performance in business organizations

Эффективное управление предприятиями нефтегазового комплекса путем анализа их финансового состояния

Данная дипломная работа освещает актуальные вопросы эффективного управления предприятиями нефтегазового комплекса путем анализа их финансового состояния. Целью работы является исследование сущности и роли финансового анализа в эффективном управлении предприятием. Рассмотрена экономическая сущность и методика анализа финансового состояния и прогнозирования деятельности предприятия нефтегазового комплекса. Показано место финансового анализа в управлении предприятием нефтегазового комплекса. Представлен анализ финансового состояния ПАО «Лукойл» и ОАО « Томскнефть». Дана оценка результатов проведенного анализа исследуемых предприятий, предложены рекомендации по использованию полученных результатов в эффективном управлении предприятием.This thesis covers relevant issues of effective management of the oil and gas companies by analyzing their financial condition. The aim of this work is to study the nature and role of financial analysis in the effective management of the enterprise. The economic essence and methods of financial analysis and forecasting activities of enterprises of oil and gas complex. Shows the place of financial analysis in enterprise management oil and gas industry. Presents an analysis of the financial condition of PJSC "LUKOIL" and OAO "Tomskneft". Evaluation of the results the conducted analysis of the studied enterprises, recommendations on the use of the results obtained in the effective management of the enterprise

The Alaska Arctic Vegetation Archive (AVA-AK)

The Alaska Arctic Vegetation Archive (AVA-AK, GIVD-ID: NA-US-014) is a free, publically available database archive of vegetation-plot data from the Arctic tundra region of northern Alaska. The archive currently contains 24 datasets with 3,026 non-overlapping plots. Of these, 74% have geolocation data with 25-m or better precision. Species cover data and header data are stored in a Turboveg database. A standardized Pan Arctic Species List provides a consistent nomenclature for vascular plants, bryophytes, and lichens in the archive. A web-based online Alaska Arctic Geoecological Atlas (AGA-AK) allows viewing and downloading the species data in a variety of formats, and provides access to a wide variety of ancillary data. We conducted a preliminary cluster analysis of the first 16 datasets (1,613 plots) to examine how the spectrum of derived clusters is related to the suite of datasets, habitat types, and environmental gradients. Here, we present the contents of the archive, assess its strengths and weaknesses, and provide three supplementary files that include the data dictionary, a list of habitat types, an overview of the datasets, and details of the cluster analysis

CMS Forward-Backward MSGC milestone

The CMS MF1 milestone was set in order to evaluate system aspects of the CMS forward-backward MSGC tracker, to check the design and feasibility of mass production and to set up assembly and test procedures. We describe the construction and the experience gained with the operation of a system of 38 MSGC detectors assembled in six multi-substrate detector modules corresponding to the geometry of the forward-backward MSGC tracker in CMS. These modules were equipped with MSGCs mounted side by side, forming a continuous detector surface of about 0.2 m2. Different designs were tried for these modules. The problems encountered are presented with the proposed solutions. Operation conditions for the 38 MSGCs are reported from an exposure to a muon beam at the CERN SPS. Gain uniformity along the wedge-shaped strip pattern and across the detector modules are shown together with the detection efficiency, the spatial resolution, alignment and edge studies

Reception Test of Petals for the End Cap TEC+ of the CMS Silicon Strip Tracker

The silicon strip tracker of the CMS experiment has been completed and was inserted into the CMS detector in late 2007. The largest sub system of the tracker are its end caps, comprising two large end caps (TEC) each containing 3200 silicon strip modules. To ease construction, the end caps feature a modular design: groups of about 20 silicon modules are placed on sub-assemblies called petals and these self-contained elements are then mounted onto the TEC support structures. Each end cap consists of 144 such petals, which were built and fully qualified by several institutes across Europe. Fro

Integration of the End Cap TEC+ of the CMS Silicon Strip Tracker

The silicon strip tracker of the CMS experiment has been completed and inserted into the CMS detector in late 2007. The largest sub-system of the tracker is its end cap system, comprising two large end caps (TEC) each containing 3200 silicon strip modules. To ease construction, the end caps feature a modular design: groups of about 20 silicon modules are placed on sub-assemblies called petals and these self-contained elements are then mounted into the TEC support structures. Each end cap consists of 144 petals, and the insertion of these petals into the end cap structure is referred to as TEC integration. The two end caps were integrated independently in Aachen (TEC+) and at CERN (TEC--). This note deals with the integration of TEC+, describing procedures for end cap integration and for quality control during testing of integrated sections of the end cap and presenting results from the testing

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701